PPARG and metabolic syndrome: By functioning as partial PPARγ agonists thisunique subset of ARBs may provide added end-organ benefits in certain patientpopulations such patients with the metabolic syndrome [87] and othercardiometabolic risk factors, including atherosclerosis, atherogenesis, and mayhave palliative effects on proliferative retinopathies.